Prestige Consumer Healthcare (NYSE:PBH) Upgraded at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a report released on Friday.

A number of other analysts have also commented on the company. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Stock Up 0.1 %

Shares of PBH opened at $76.79 on Friday. The firm has a 50 day simple moving average of $80.08 and a two-hundred day simple moving average of $74.93. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. Prestige Consumer Healthcare has a one year low of $60.00 and a one year high of $86.36. The company has a market cap of $3.79 billion, a P/E ratio of 18.68, a P/E/G ratio of 2.17 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.07 earnings per share. Research analysts forecast that Prestige Consumer Healthcare will post 4.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its position in Prestige Consumer Healthcare by 19.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after purchasing an additional 255,045 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Congress Asset Management Co. increased its holdings in Prestige Consumer Healthcare by 7.8% during the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock worth $62,375,000 after buying an additional 62,411 shares during the last quarter. Boston Trust Walden Corp increased its holdings in Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock worth $64,942,000 after buying an additional 252,089 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Prestige Consumer Healthcare by 0.8% in the second quarter. The Manufacturers Life Insurance Company now owns 543,401 shares of the company’s stock worth $37,413,000 after acquiring an additional 4,305 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.